Serial Low Doses of Sorafenib Enhance Therapeutic Efficacy of Adoptive T Cell Therapy in a Murine Model by Improving Tumor Microenvironment

被引:34
作者
Chuang, Hui-Yen [1 ]
Chang, Ya-Fang [1 ]
Liu, Ren-Shyan [2 ,3 ]
Hwang, Jeng-Jong [1 ]
机构
[1] Natl Yang Ming Univ, Dept Biomed Imaging & Radiol Sci, Taipei 112, Taiwan
[2] Taipei Vet Gen Hosp, Natl PET Cyclotron Ctr, Taipei, Taiwan
[3] Taipei Vet Gen Hosp, Dept Nucl Med, Taipei, Taiwan
关键词
HEPATOCELLULAR-CARCINOMA; IN-VIVO; EFFECTOR FUNCTIONS; ANTITUMOR-ACTIVITY; SUPPRESSOR-CELLS; TRANSCRIPTION; FAS LIGAND; CANCER; IMMUNOTHERAPY; IMMUNITY;
D O I
10.1371/journal.pone.0109992
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
070301 [无机化学]; 070403 [天体物理学]; 070507 [自然资源与国土空间规划学]; 090105 [作物生产系统与生态工程];
摘要
Requirements of large numbers of transferred T cells and various immunosuppressive factors and cells in the tumor microenvironment limit the applications of adoptive T cells therapy (ACT) in clinic. Accumulating evidences show that chemotherapeutic drugs could act as immune supportive instead of immunosuppressive agents when proper dosage is used, and combined with immunotherapy often results in better treatment outcomes than monotherapy. Controversial immunomodulation effects of sorafenib, a multi-kinases inhibitor, at high and low doses have been reported in several types of cancer. However, what is the range of the low-dose sorafenib will influence the host immunity and responses of ACT is still ambiguous. Here we used a well-established E.G7/OT-1 murine model to understand the effects of serial low doses of sorafenib on both tumor microenvironment and transferred CD8+ T cells and the underlying mechanisms. Sorafenib lowered the expressions of immunosuppressive factors, and enhanced functions and migrations of transferred CD8+ T cells through inhibition of STAT3 and other immunosuppressive factors. CD8+ T cells were transduced with granzyme B promoter for driving imaging reporters to visualize the activation and distribution of transferred CD8+ T cells prior to adoptive transfer. Better activations of CD8+ T cells and tumor inhibitions were found in the combinational group compared with CD8+ T cells or sorafenib alone groups. Not only immunosuppressive factors but myeloid derived suppressive cells (MDSCs) and regulatory T cells (Tregs) were decreased in sorafenib-treated group, indicating that augmentation of tumor inhibition and function of CD8+ T cells by serial low doses of sorafenib were via reversing the immunosuppressive microenvironment. These results revealed that the tumor inhibitions of sorafenib not only through eradicating tumor cells but modifying tumor microenvironment, which helps outcomes of ACT significantly.
引用
收藏
页数:11
相关论文
共 58 条
[1]
Combinatorial drug therapy for cancer in the post-genomic era [J].
Al-Lazikani, Bissan ;
Banerji, Udai ;
Workman, Paul .
NATURE BIOTECHNOLOGY, 2012, 30 (07) :679-691
[2]
Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy [J].
Azad, Nilofer S. ;
Aragon-Ching, Jeanny B. ;
Dahut, William L. ;
Gutierrez, Martin ;
Figg, William D. ;
Jain, Lokesh ;
Steinberg, Seth M. ;
Turner, Maria L. ;
Kohn, Elise C. ;
Kong, Heidi H. .
CLINICAL CANCER RESEARCH, 2009, 15 (04) :1411-1416
[3]
Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice [J].
Breart, Beatrice ;
Lemaitre, Fabrice ;
Celli, Susanna ;
Bousso, Philippe .
JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (04) :1390-1397
[4]
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial [J].
Brose, Marcia S. ;
Nutting, Christopher M. ;
Jarzab, Barbara ;
Elisei, Rossella ;
Siena, Salvatore ;
Bastholt, Lars ;
de la Fouchardiere, Christelle ;
Pacini, Furio ;
Paschke, Ralf ;
Shong, Young Kee ;
Sherman, Steven I. ;
Smit, Johannes W. A. ;
Chung, John ;
Kappeler, Christian ;
Pena, Carol ;
Molnar, Istvan ;
Schlumberger, Martin J. .
LANCET, 2014, 384 (9940) :319-328
[5]
Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma [J].
Busse, Antonia ;
Asemissen, Anne Marie ;
Nonnenmacher, Anika ;
Braun, Floriane ;
Ochsenreither, Sebastian ;
Stather, David ;
Fusi, Alberto ;
Schmittel, Alexander ;
Miller, Kurt ;
Thiel, Eckhard ;
Keilholz, Ulrich .
EUROPEAN JOURNAL OF CANCER, 2011, 47 (05) :690-696
[6]
Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma [J].
Cabrera, Roniel ;
Ararat, Miguel ;
Xu, Yiling ;
Brusko, Todd ;
Wasserfall, Clive ;
Atkinson, Mark A. ;
Chang, Lung Ji ;
Liu, Chen ;
Nelson, David R. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (04) :737-746
[7]
Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model [J].
Cao, Mengde ;
Xu, Yiling ;
Youn, Je-in ;
Cabrera, Roniel ;
Zhang, Xiaokui ;
Gabrilovich, Dmitry ;
Nelson, David R. ;
Liu, Chen .
LABORATORY INVESTIGATION, 2011, 91 (04) :598-608
[8]
Immunomodulation of Curcumin on Adoptive Therapy with T Cell Functional Imaging in Mice [J].
Chang, Ya-Fang ;
Chuang, Hui-Yen ;
Hsu, Chien-Hui ;
Liu, Ren-Shyan ;
Gambhir, Sanjiv Sam ;
Hwang, Jeng-Jong .
CANCER PREVENTION RESEARCH, 2012, 5 (03) :444-452
[9]
Bcl-2 overexpression enhances tumor-specific T-cell survival [J].
Charo, J ;
Finkelstein, SE ;
Grewal, N ;
Restifo, NP ;
Robbins, PF ;
Rosenberg, SA .
CANCER RESEARCH, 2005, 65 (05) :2001-2008
[10]
Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity [J].
Chen, Mei-Ling ;
Yan, Bo-Shiun ;
Lu, Wan-Chih ;
Chen, Mei-Huei ;
Yu, Sung-Liang ;
Yang, Pan-Chyr ;
Cheng, Ann-Lii .
INTERNATIONAL JOURNAL OF CANCER, 2014, 134 (02) :319-331